Oxyglobin

Quick links to important sections

Oxyglobin

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxyglobin

Property Description
Active Ingredient Haemoglobin glutamer-200 (Bovine)
Form Sterile Intravenous Solution (IV)
Pharmacological Class Hemoglobin-Based Oxygen Carrier (HBOC)
Unique Feature Only approved veterinary HBOC in US and EU
Origin Bovine (Cattle) Source

What Type of Medicine is Oxyglobin?

Oxyglobin is an intravenous solution classified as a hemoglobin-based oxygen carrier (HBOC) that functions as a specialized blood substitute for veterinary use. It is a sterile, liquid solution administered directly into the bloodstream to enhance oxygen delivery.

Oxyglobin is distinctive as it was the first HBOC approved for clinical use in key regulatory regions. This specialized drug is universally compatible and does not require type-matching, which is a significant practical advantage over traditional whole blood transfusions. This means it helps deliver oxygen to tissues without the need for traditional blood typing.


What is Oxyglobin Made Of and Where Does it Come From?

The active component in Oxyglobin is purified and modified hemoglobin that originates from a bovine (cattle) source, specifically referred to as Haemoglobin glutamer-200 (bovine). This protein is carefully extracted and chemically stabilized through polymerization.

The polymerization process prevents the rapid breakdown of cell-free hemoglobin, ensuring the product can remain functional in circulation for a necessary period. The use of a bovine source, combined with its specialized manufacturing, grants it a remarkable stability for ready-to-use application, which is a major logistical differentiator from refrigerated blood products.


What is the General Purpose of Oxyglobin?

The general purpose of Oxyglobin is to dramatically increase the oxygen-carrying capacity of the blood to ensure critical tissues receive adequate oxygen during acute deficits. It is often used as an "Oxygen Bridge," temporarily stabilizing a patient and preventing tissue damage until the body can either receive a transfusion or generate its own red blood cells.

Its ability to support systemic oxygenation, even when blood vessel flow is compromised, makes it a vital tool in urgent care situations. It serves as a means of providing immediate oxygen support when conventional blood products are unavailable.

What side effects are possible with Oxyglobin?

Oxyglobin (Haemoglobin glutamer-200 (Bovine)) has an officially documented safety profile characterized by specific adverse reactions and usage constraints, as defined in regulatory texts.


Officially Documented Adverse Reactions

The most frequently observed adverse reactions are generally related to the medicine's properties as a plasma volume expander, while others are related to the active component's systemic presence and metabolism.

Frequency and System-Organ Classes

The following table summarizes the key adverse reactions as classified by regulatory authorities:

Classification Adverse Reactions (Examples)
Commonly Observed Circulatory overload, pulmonary oedema, vomiting, loss of appetite, fever
Occasionally Noted Diarrhoea, cardiac arrhythmias
Metabolic/Excretory Yellow/orange discoloration of the skin, mucous membranes, sclera, discoloured urine

Circulatory overload and its associated signs, such as tachypnea (rapid breathing) and pulmonary oedema (fluid in the lungs), are among the most commonly observed and clinically significant adverse events.


Key Safety Constraints and Restrictions

Specific limitations on use are documented within the regulatory labeling:

  • Contraindications: The medicine is officially contraindicated for use in patients with a predisposition to circulatory overload, including those with advanced cardiac disease or severely impaired cardiac function.
  • Re-treatment Restriction: The product should not be administered to individuals who have been previously treated with Oxyglobin.
  • Diagnostic Interference: The presence of the medicine in plasma samples can interfere with colorimetric serum chemistry tests, potentially leading to artifactual changes in results, a factor that must be considered during laboratory evaluation.
  • Specific Populations: The safety of use in pregnant or lactating individuals has not been officially determined.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Haemoglobin glutamer-200 (Bovine) defines overdosage primarily as the result of an excessive rate of administration, specifically rates greater than 10 ml/kg/h. Such over-infusion may lead to immediate cardiopulmonary effects, which are considered severe or life-threatening manifestations.


Documented Manifestations and Emergency Action

Official labeling documents that overdose may present as circulatory overload. Recognized clinical signs include tachypnea (rapid breathing), dyspnea (difficulty breathing), and harsh lung sounds, potentially escalating to pulmonary oedema or cardiac arrhythmias.


Required Help-Seeking and Management

Immediate discontinuation of the infusion is mandatory upon recognizing signs of overdosage or an excessive rate of administration. Urgent medical attention is required to manage any persistent or severe cardiopulmonary effects. Regulatory guidance confirms that management is limited to symptomatic and supportive treatment, as no specific antidote is known for Oxyglobin overdosage.

Therapeutic Uses of Oxyglobin

What Oxyglobin Treats: Main Uses and Benefits

Oxyglobin (Haemoglobin glutamer-200 (Bovine)) is considered relevant for addressing conditions in canine patients associated with a critical deficit in the blood's oxygen-carrying capacity. Its primary role is to provide supportive therapeutic benefit when symptoms are acute, and it may assist with maintaining functional stability during a critical period.

The product is commonly used across conditions presenting with anemia in dogs. The medication is applied to manage pronounced, systemic symptoms related to organ-specific functional stress. This is commonly used to help with managing severe physical compromise, such as profound lethargy, debilitating weakness, or physical collapse, and addressing compensatory responses like accelerated heart rate (tachycardia) and rapid breathing (tachypnea).

Oxyglobin is relevant in clinical situations where the patient suffers from severe anemia or acute blood loss caused by trauma or disease. It is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as emergency medicine and intensive care unit (ICU) support. This treatment provides supportive relief when symptoms intensify and may assist with maintaining functional stability.


Quick Fact: Symptomatic Support

Oxyglobin is relevant for easing symptoms that create noticeable physiological strain, specifically those clustering around symptoms related to systemic imbalance and physical collapse.

Regulatory References

  1. U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxyglobin?

Oxyglobin (Haemoglobin glutamer-200 (Bovine)) is strictly a veterinary medicine approved for the treatment of anemia in dogs (canine patients). Eligibility is defined by the target species and specific contraindications related to the risk of fluid imbalance.

Populations Excluded from Use

The medicine is contraindicated (must not be used) in dogs with pre-existing conditions that pose a risk of circulatory compromise:

  • Dogs with advanced cardiac disease, severely impaired cardiac function, or other predisposition to circulatory overload.
  • Dogs presenting with oliguria or anuria (minimal or no urine output).
  • Dogs previously treated with Oxyglobin (it is a single-use treatment).

Use Not Established or Determined

Official regulatory documents indicate that the medicine's safety has not been determined for pregnant or lactating bitches. Furthermore, safety and efficacy have not been evaluated in dogs with thrombocytopenia with active bleeding, meaning use in these populations is not established in the product labeling. The administration of Oxyglobin is restricted to use by or on the order of a licensed veterinarian.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oxyglobin (Haemoglobin glutamer-200 (Bovine)) has a specific interaction profile documented in regulatory sources that is primarily characterized by the absence of traditional drug-drug interactions and the presence of procedural restrictions based on physical incompatibility and diagnostic interference.

Documented Interaction Status

Official regulatory labeling explicitly states there are no known pharmacokinetic or pharmacodynamic interactions with other medicinal products. The same status applies to interactions with food, alcohol, herbal products, and supplements.

Interaction Type Official Regulatory Statement
Drug–Drug, Food, Substance None known
Co-administration with Blood Not contraindicated (e.g., with whole blood transfusion)

Interaction-Related Restrictions

Regulatory documents impose mandatory constraints related to administration and post-treatment analysis:

  • Physical Incompatibility: Oxyglobin must not be administered concurrently with other intravenous fluids or medicinal products using the same infusion set or catheter.
  • Co-mingling Restriction: Other medications or solutions must not be added directly to the Oxyglobin infusion bag.
  • Diagnostic Test Interference: The product's presence in serum may interfere with common laboratory assays. This includes colorimetric serum chemistry tests (potentially causing artifactual results) and optical methods used for coagulation assays (e.g., PT and aPTT), which are not reliable after administration.

Mechanism of Action

How Oxyglobin Works

Oxyglobin (Haemoglobin glutamer-200) functions through a cascade of three distinct, interacting mechanisms: direct oxygen transport, modulation of vascular tone, and colloid-driven volume expansion.


Cell-Free Oxygen Transport and Diffusion

The polymerized bovine hemoglobin acts as a rapid, extra-cellular oxygen carrier, binding O2 at the heme iron (Fe^2+) site. Due to its cell-free and relatively small size, it increases the oxygen content of the plasma and enhances the diffusive oxygen transport into highly constricted or poorly perfused microvascular areas. This mechanism contributes to the increase of tissue oxygen tension, a key physiological consequence of enhanced oxygen diffusion.


Inherent Vascular Tone Modulation

The molecule's cell-free nature causes it to avidly scavenge and inactivate Nitric Oxide (NO) in the plasma. Since NO is the key mediator for vessel relaxation, its removal leads to unopposed smooth muscle contraction, resulting in an increase in systemic vascular resistance (SVR). This mechanistic consequence defines the molecule's unique hemodynamic profile.


Colloid-Mediated Plasma Volume Effect

The large, stable size of the hemoglobin polymer exerts a high plasma oncotic pressure. This physical property draws water from the extravascular space into the circulation. This fluid mobilization produces a transient expansion of the circulating plasma volume. The colloid effect and volume expansion alter fluid dynamics, influencing the overall circulation and the volume available for oxygen distribution.

Dosage and Administration Information

The administration of Oxyglobin (Haemoglobin glutamer-200 (Bovine)) adheres to a single-course protocol. The medicine is for Intravenous (IV) Infusion and is intended to provide short-term oxygen-carrying support.

Dosing and Rate Instructions

The volume of solution is calculated based on the patient's body weight, utilizing the 130 mg/mL sterile solution.

Property Instruction
Dosing Range A single dose of 10 to 30 mL/kg of body weight.
Maximum Rate The infusion must be administered slowly, at a rate not exceeding 10 mL/kg/hr.
Frequency Single administration only.

Preparation and Procedural Rules

The drug requires controlled handling prior to and during delivery. The solution may be warmed to 37°C before use. A critical procedural rule is that the solution must not be mixed with any other intravenous fluids or medications in the administration line to prevent alteration of the product. Aseptic technique is required for administration via a standard infusion set. Once the product is prepared, its use must occur within 24 hours of the overwrap being removed. These instructions define the precise parameters for the delivery of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oxyglobin

This section reviews the formal research and official studies concerning Oxyglobin (Haemoglobin Glutamer-200 (Bovine)), detailing the types of evidence that exist, what was measured in those studies, and where research remains uncertain. The information presented here describes group patterns observed in the studies and contributes to the broader evidence landscape, but findings describe group patterns, not personal outcomes.

Evidence for Use in Anemia in Dogs

Oxyglobin was studied for use in dogs with clinical anemia, which is a condition marked by functional limitations due to a critical lack of oxygen-carrying capacity in the blood. Research included cases of anemia resulting from various causes, such as acute blood loss or red blood cell destruction.

The foundation of the evidence relies on multi-center, randomized clinical field trials as documented in regulatory reviews. These studies examined outcomes related to systemic or functional imbalance, primarily focusing on changes in oxygen delivery markers over the short term. Researchers monitored objective physiological measures, such as plasma hemoglobin concentration, and used clinical scales to assess the evolution of physical signs associated with an oxygen deficit, including lethargy and heart rate.

In these studies, regulatory submissions reported measurements of plasma hemoglobin concentration changes following administration. Clinical trial data described patterns of change in the observed clinical signs of anemia over a short-term observation period.

Comparative Studies and Research Design

The structure of the key studies involved controlled designs where the product was evaluated in comparison to an untreated control group or used controlled scenarios to compare it against established blood products. These studies explored how patterns of temporary physiological imbalance varied when comparing the product to traditional transfusions of packed red blood cells (pRBCs). Reports on the comparison studies described patterns related to measured variables such as blood gas and blood pressure between groups.

What is Still Uncertain About Oxyglobin Research

Evidence highlights what is known and what is still uncertain. The regulatory trials, while categorized in regulatory reviews, had certain limitations.

Long-term effects are not fully established, and follow-up durations were limited in the main clinical trials. For instance, the primary time interval for assessing the measured changes in clinical signs was observed in a short-term period, typically 24 hours post-administration. Additionally, a key finding of the research was observed in some studies that the product may interfere with the accuracy of results from several common colorimetric laboratory tests, which complicates post-administration monitoring.

Key Studies & References

  1. U.S. FDA Center for Veterinary Medicine Freedom of Information Summary for Oxyglobin

Frequently Asked Questions (FAQ)

Common questions about Oxyglobin (FAQ)

Q: How quickly does Oxyglobin start to work after it's given?

A: According to regulatory documents, the medicine is a specialized oxygen-carrying fluid administered directly into the bloodstream. This means it is intended to function rapidly to increase the hemoglobin concentration in the plasma, which helps to increase the arterial oxygen content.


Q: How long does the effect of a single Oxyglobin dose last?

A: Official product information indicates that the plasma half-life of the product is approximately 30 to 40 hours. The active component is noted to be eliminated from the plasma within about five to seven days.


Q: Is Oxyglobin safe for dogs with kidney issues?

A: The medicine is officially contraindicated (must not be used) in patients at high risk of circulatory compromise. This includes those with severely impaired cardiac function or those with minimal or no urine output (a condition known as oliguria or anuria).


Q: What are the most common things people worry about after a pet receives Oxyglobin?

A: The official documentation lists several commonly observed adverse effects, many of which relate to the product's ability to increase fluid volume. These include signs of fluid buildup (such as rapid breathing), vomiting, loss of appetite, and fever.


Q: Can a dog be allergic to Oxyglobin?

A: The official regulatory lists of undesirable effects do not specifically use the term 'allergic reaction' or 'hypersensitivity' to describe common or occasional side effects. Patients are carefully monitored for any unexpected reaction during administration.


Q: Is it true that Oxyglobin can change the color of a dog's urine?

A: Yes, official documents note that discolored or turbid urine is an expected effect following administration. This is due to the natural metabolism and excretion process of the product’s hemoglobin components by the body.


Q: What is the evidence that Oxyglobin improves oxygen delivery?

A: Regulatory review of clinical studies reports that the product increases the concentration of hemoglobin in the plasma and overall blood. This increase in arterial oxygen content is associated with enhanced oxygen availability for tissues.


Q: Does Oxyglobin affect the results of standard blood tests?

A: Official warnings indicate that the product's presence in a blood sample may interfere with many common laboratory tests. Specifically, it can cause artifactual changes in results from colorimetric serum chemistry tests and optical methods used for coagulation assays.


Q: What kind of monitoring is done during the administration of Oxyglobin?

A: Precautions state that patients should be carefully monitored for signs of circulatory overload, such as changes in heart rate or respiratory rate. Monitoring is essential to ensure the patient is responding appropriately during the administration process.


Q: Does Oxyglobin contain any components that could transmit disease?

A: The active ingredient in Oxyglobin is purified, modified, cell-free hemoglobin derived from a bovine source. The regulatory approval process includes specialized procedures intended to remove potential contaminants during manufacturing to create a sterile solution.


Q: How does Oxyglobin affect blood pressure?

A: The medicine's mechanism involves scavenging nitric oxide, a substance that naturally relaxes blood vessels. This effect can lead to blood vessel tightening, resulting in an increase in systemic vascular resistance (SVR), which is a factor that influences overall blood pressure.


Q: Do dogs need special preparation before getting Oxyglobin?

A: Official guidance indicates that patients should not be over-hydrated before the product is administered, as a precaution. Additionally, the solution itself may be warmed to 37 C (body temperature) immediately before use, according to procedure.


Q: What is the shelf life of Oxyglobin?

A: When stored correctly at a temperature not exceeding 30 C, the sealed 125 mL bag has an official shelf-life of up to five years. Once the protective overwrap is removed for use, the solution must be administered within 24 hours.


Q: Why does the packaging or product guide mention monitoring of plasma color?

A: Monitoring plasma color is important because the active ingredient can cause a yellow/orange discoloration of the patient's plasma. This discoloration can interfere with certain colorimetric laboratory tests, making it a critical factor for accurate post-treatment evaluation.


Q: Can Oxyglobin mask or hide certain underlying medical problems?

A: Official warnings state that the product may interfere with the accuracy of results from several common colorimetric laboratory tests. This diagnostic interference can complicate the evaluation of the patient's underlying conditions or other concurrent issues.


Q: What does the drug's purpose section say about its use in non-anemic patients?

A: The medicine is officially indicated (approved) by regulatory bodies only for the treatment of anemia in dogs. Its use is strictly defined for patients with this condition, and usage outside of this defined purpose is not established in the product labeling.


Q: Does Oxyglobin have specific temperature requirements during and after use?

A: Yes, the product must not be frozen and should be stored below 30 C. For administration, the solution may be warmed to 37 C. This is done to ensure the product is handled correctly according to official guidelines.


Q: Does receiving Oxyglobin feel painful for the pet?

A: The official guidance specifies that the product is delivered as a sterile intravenous (IV) infusion via a standard catheter and infusion set. This is the established method of administration for this specialized veterinary product.


Q: What happens to Oxyglobin in the body after it has done its job?

A: According to pharmacokinetic information, the components are progressively incorporated into the body's protein pool. The heme degrades into bile pigments, such as bilirubin, and is primarily excreted through the kidneys.

How should Oxyglobin be stored and disposed of?

Storage Conditions

Oxyglobin (Haemoglobin glutamer-200 (Bovine)) must be stored at a temperature not above 30°C and it is strictly prohibited to freeze the solution. The product should be stored in its original container, which provides a shelf-life of up to five years for the 125 mL bag.

Once the protective overwrap is removed, the solution must be used within 24 hours. The product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused veterinary medicinal product or waste materials derived from the use of Oxyglobin must be disposed of in accordance with local requirements. Disposal must follow established local guidelines for handling veterinary medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxyglobin found in:

A-Z Index: